Veeva Systems (VEEV)

By both methods, the value today (DCF $242 · Multiples $254) is below the market price ($296).

Today — expensive, no margin of safety: at $296 trades ~16.3% above its value discounted to today (~$254); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Preserva valor: the target price ($317) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$158.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($296) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The price discounts growth (18.9%/year) above our base case (13.0%/year) → it is priced for a demanding scenario and leaves little cushion against a slowdown.

That growth implies ~$2 bn of owner earnings in year 5 (vs ~$1.5 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on NOPAT. In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 is the TTM ended Jul 31, 2026 (second quarter of fiscal 2027, reported in the 8-K of Aug 26, 2026; revenue $3,458M, +16.5% year over year). Year 1 starts from the company's own current guidance in that same release (§5 R1 previa: guidance overrides the trajectory when it exists, because it carries information the annual filing does not), read through its two anchors: fiscal 2027 revenue of $3,682-3,687M and non-GAAP diluted earnings per share of approximately $9.21, with non-GAAP operating income of about $1,640M. Against closed fiscal 2026 ($3,195M), the guided midpoint implies +15.3%. ⚠️ That 15.3% is the fiscal-year figure, not the model's window, which is rolling: year 1 runs from August 2026 to July 2027 and is built from levels off the same guidance — the third quarter is guided at $932-935M and the fourth is implied at $940M by subtracting the already-reported half year from the guided total, that is $1,874M of second-half revenue against $1,647M a year earlier (+13.8%); with the first half of fiscal 2028 growing at the same pace, the window comes to $3,938M, +13.9% over year 0. That is why the path keeps the 13.9% of the previous re-anchoring even though realized year 0 beat the model by 2.6 points: what accelerated was the reported quarter (+17.6% year over year), and the company itself guides the following half year to decelerate. From there the path decays smoothly to 11.0% in year 5, reflecting the maturation of the high-double-digit growth of the last two fiscal years (16.2% and 16.3%) as the customer base approaches most of the large global pharmaceutical companies. The GAAP operating margin is re-anchored to the real TTM figure (29.93%, against 28.8% in the previous cut) and expands toward 33.0% in year 5 on operating leverage — stock-based compensation grows more slowly than revenue as the employee base matures. The guided non-GAAP margin (44.5% at the midpoint) is not comparable with that path and is not copied over: it excludes precisely the stock-based compensation and the amortization of intangibles that the method expenses. The valuation metric is EV/NOPAT (not maintenance cash flow, nor adjusted earnings before depreciation): NOPAT expenses stock-based compensation by construction through GAAP operating income, avoiding the trap of adding it back, which inflates reported cash flow (§3). Capital expenditure is minimal (net property and equipment of just $73M on $3,458M of revenue): a cloud software business with no physical infrastructure of its own, funded entirely with internally generated cash and carrying no debt. Cash accumulates and no buyback is modeled: the $2,000M program authorized in January 2026 is recent and the three-year series of diluted shares still shows modest net dilution, so there is no sustained net reduction to project (§6: when in doubt, less buyback). The base-case exit multiple (24 times) sits in the middle of the enterprise software band (20-30 times), below the ceiling because of the declared risk of moat erosion in Commercial Solutions (customers migrating from Veeva CRM to Salesforce).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (EV falls as cash increases). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $317 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $296, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $317 in 5 years and a required return of 4.5% annually, the maximum to pay today is $254. Against the current market price ($296), the margin of safety is -16.3% (trades above the maximum → a premium is paid) and the total return at that price would be 1.4% annually.

• Entry multiple vs. archetype band. The base-case exit multiple (24x) sits at the midpoint of the enterprise-software band (20-30x).
• Expected 5-year return. The verdict is Preserves value, with a CAGR of +1% at the market price.
• Margin of safety. No margin of safety: at this price capital is preserved, but it is not bought below its value.
• Net cash not reflected in the simple multiple. More than US$7,000M of debt-free net cash separates the value of the operating business from the total enterprise value.
• Sensitivity to the terminal multiple. The adverse scenario compresses the multiple to 19x and the favorable scenario expands it to 29x, both within or near the archetype band.
• Reverse approach (reverse DCF). The growth implied by the current price is compared automatically against the model's base path.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (106%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Return on capital. Asset-light business financed with own cash, no debt; return on invested capital is well above the 10% bar.
• Cash generation. Operating cash flow of more than US$1,600M over the trailing twelve months, with minimal capex given the asset-light nature of the business.
• Reinvestment runway. Limited reinvestment in physical capital; future growth depends on product R&D and Veeva AI expansion, not traditional capex.
• Earnings quality. GAAP earnings include non-recurring litigation charges (US$30.6M in the latest fiscal year, versus US$5.0M the prior year).
• Stock-based compensation trap. The NOPAT-based valuation expenses stock-based compensation by construction, avoiding the trap of adding it back as reported FCF or adjusted EBITDA do.
• Balance sheet. More than US$7,300M in cash and short-term equivalents, zero total debt.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Veeva's main driver is customer volume times subscription price, not a physical volume indicator. Total customer growth (+5.1% year over year) is slower than revenue growth (+16.3%), confirming that most of the growth comes from expansion within the existing base (more modules, more users, higher price per customer) rather than adding new logos — consistent with a company that already serves most of the world's large pharmaceutical companies and whose future growth depends on deepening the relationship with each customer and on adoption of Veeva AI. The Commercial Solutions segment grew slower in customers (+5.1%) than R&D and Quality Solutions (+6.3%), and its subscription revenue also grew slower (15.0% vs 19.8%), consistent with the declared competitive pressure.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (31-jul-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Recent trajectory. Growth accelerated from 9.7% (FY24) to 16.2%-16.3% (FY25-FY26) and is now decelerating toward the 13.9% guided for FY27.
• Current guidance. The company guided revenue of US$3,635-3,645M for fiscal 2027, +13.9% at the midpoint.
• Segment mix. R&D and Quality Solutions (55% of revenue) grows faster (20.7%) than Commercial Solutions (11.4%), the segment under competitive pressure.
• Customer expansion vs. new logos. Total customers grew 5.1% while revenue grew 16.3%: the engine is expansion within the existing base, not new-logo acquisition.
• New lines (AI). Veeva AI, Ostro, and Veeva Falcon are recent additions with no monetization track record yet measurable in reported revenue.
• Risk of forced reacceleration. The model does not assume a reacceleration: the path decays smoothly from the 13.9% guidance toward 11.0% in year 5, with no jumps.

• Revenue recurrence. Subscription revenue, 84% of the total and growing 17% year over year, with multi-year contracts in a regulated industry.
• Product differentiation. Software purpose-built for the life sciences industry, not a generic platform adapted to fit.
• Moat direction. In declared erosion in Commercial Solutions from the migration to Vault CRM and Salesforce competition.
• Pricing power. Large renewals show increasing scrutiny and pricing pressure, per the filing itself.
• Operating leverage. GAAP operating margin went from 18.2% to 28.7% over two fiscal years on cost-base leverage.
• Behavior in adverse cycles. The business depends on the health of the life sciences sector and its funding; there is no recent recession track record to test it.
• Customer concentration. The top ten customers account for 28% of total revenue in each of the last three fiscal years.

• ✓Leverage (net debt / EBITDA)Net cash $7.3 bn
• –Interest coverage (EBIT / interest)no data
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 106% of ROIC
• !Value creation (ROIC − 10% bar)+4pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.5x — no over-investment
• ✓Float / working capitalFrees up cash $0 bn (float / negative WC)
• !Dilution (SBC % of revenue + shares)SBC 14.3% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Debt. Zero total debt; the balance sheet carries no financial leverage.
• Liquidity. More than US$7,300M in cash and short-term equivalents, well above any operating working-capital need.
• Cash flow. Operating cash flow of more than US$1,600M over the trailing twelve months, with minimal capex.
• Off-balance-sheet commitments. Operating lease commitments for office space, with no associated financial debt.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Founder at the helm. Peter Gassner, founder and CEO since the company's inception, described in the 10-K as critical to its strategic vision and direction.
• Corporate structure. Public Benefit Corporation: the board balances shareholder return with other stakeholders, a mandate that can, in theory, dilute a pure focus on shareholder value.
• Capital allocation. No debt, cash accumulated over years, and only in 2026 a US$2,000M buyback program; the historical discipline was to conserve cash more than to return it.
• Stock-based compensation. 14.5% of revenue and 28.8% of cash flow, a high level that dilutes shareholders unless offset by sustained buybacks.

• Relative missing buyers: the market discounts the risk of customer migration to Salesforce in the CRM segment without distinguishing it from the R&D and Quality Solutions business, which grows faster and has a more stable moat
• The filing itself discloses the risk of customer defection during the Vault CRM transition, which penalizes the consolidated multiple even though it only affects part of the business
• Net cash of more than US$7,000M is not clearly separated from the operating business in market perception, which can obscure how much of the valuation is business versus surplus cash
• Sustained high-teens growth (16%+ over the last two fiscal years) that the market may be extrapolating downward excessively at the mere mention of the Salesforce risk

The combination of a partially eroded moat in the largest segment with substantial, debt-free net cash is unusual: the market tends to set a single consolidated multiple instead of recognizing that R&D and Quality Solutions (55% of revenue) sustains its moat better than Commercial Solutions. If the migration to Vault CRM executes without material customer defection, there is room for the consolidated multiple to move toward the top of the enterprise-software band.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -7%/year (-32% total): the margin of safety protects the downside. The bull (+7%/year, +38% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Veeva CRM migration to Salesforce. Veeva CRM support ends Dec 31, 2029; customers have already announced intent to migrate to Salesforce during the transition to Vault CRM.
• Customer concentration. The top ten customers account for 28% of total revenue in each of the last three fiscal years.
• Dependence on the life sciences sector. Changes in drug pricing policy, funding cuts to the FDA/NIH, or reduced biotech funding hit demand directly.
• Intensifying competition. Salesforce, IQVIA, Oracle, Microsoft, Dassault Systèmes, and Honeywell compete across different lines, with new entrants making better use of artificial intelligence.
• Data security. Processes sensitive patient and healthcare-professional data; a security breach would damage perceived reliability of its solutions.
• Litigation and non-recurring charges. Litigation charges went from US$5.0M to US$30.6M in the latest fiscal year.
• Public Benefit Corporation structure. The mandate to balance multiple stakeholders' interests can, in theory, limit decisions that purely maximize shareholder value.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A fast grower growing 13% at a multiple/growth of 4.1 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 2% (EBIT/EV) + ROIC 14% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 19% vs our 13%: priced for perfection, no favorable mispricing.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -7%/yr, bull-scenario ceiling +7%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: switching costs, network effects, efficient scale, intangibles → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  The price demands 19% growth, far above our 13% — heroic assumptions.